Tourmaline Bio, Inc. (NASDAQ: TRML), a late-stage clinical biotechnology company, has announced positive topline results from its ongoing Phase 2 TRANQUILITY trial. The trial evaluates the efficacy of pacibekitug, an IL-6 inhibitor, in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease. The study demonstrated rapid, deep, and durable reductions in high-sensitivity C-reactive protein (hs-CRP) levels through Day 90 across all pacibekitug arms, achieving statistical significance (p<0.0001) compared to placebo. Notably, the 50 mg quarterly dosing arm achieved over 85% reduction in hs-CRP from baseline. The adverse events in the trial were comparable to placebo. These results support advancing pacibekitug into a potential Phase 3 cardiovascular outcomes trial in atherosclerotic cardiovascular disease and a planned Phase 2 proof-of-concept trial for abdominal aortic aneurysm, expected to initiate in the second half of 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.